病症中的RIPK1表达和抑制:对神经炎症和神经保护的影响
Ignacio Silva-Llanes1,2,3, Enrique Madruga4,5, Ana Martínez4,5
1Department of Biochemistry, School of Medicine, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Frontiers in neuroscience
|February 11, 2025
概括
受体相互作用蛋白激酶1 (RIPK1) 在陶病症中升高. 抑制RIPK1降低了炎症,但并没有在小鼠模型中预防神经退行,这表明这些疾病的复杂炎症途径.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 包括前性痴呆症 (FTD),渐进性超核性麻 (PSP) 和阿尔茨海默病 (AD) 在内的陶氏病,以TAU蛋白聚合和神经炎症为特征.
- 受体相互作用蛋白激酶1 (RIPK1) 在与病相关的神经炎症过程中起着至关重要的作用.
- 由于缺乏生物标志物和有效的药理学标,目前对病的治疗策略有限.
研究的目的:
- 调查RIPK1在各种陶病变的作用,包括初级 (PSP) 和二级 (AD) 形式.
- 在FTD小鼠模型中评估RIPK1抑制剂 (GSK2982772) 的治疗潜力.
主要方法:
- 在FTD小鼠模型和来自PSP和AD患者的人类大脑组织样本中分析RIPK1mRNA水平.
- 给一种过度表达TAU (TAU P301L) 的小鼠模型注射RIPK1抑制剂GSK2982772.
- 在治疗后评估海马体中反应性天体细胞反应和神经退行.
主要成果:
- 在不同病症的小鼠模型和人体样本中观察到RIPK1mRNA水平升高.
- 在小鼠中,GSK2982772治疗显著降低了TAU P301L诱导的反应性天体细胞反应.
- 该RIPK1抑制剂没有提供对TAU P301L诱导的海马神经退行症的神经保护.
结论:
- 在各种多病症中,RIPK1被上调,这表明它与疾病有关.
- 向RIPK1可能会调节神经炎症,特别是球症,在陶氏病变中.
- 抑制RIPK1的有限的神经保护作用凸显了tau诱导的神经退行症中炎症途径的复杂性,并表明可能需要额外的点.
相关概念视频
Enzyme-linked Receptors
77.1K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.1K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


